{"nctId":"NCT00483938","briefTitle":"The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)","startDateStruct":{"date":"2007-06"},"conditions":["Hepatitis C, Chronic"],"count":236,"armGroups":[{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group A)","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated-interferon Alfa-2a","Drug: Ribavirin"]},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group B)","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated-interferon Alfa-2a","Drug: Ribavirin"]},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group C)","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated-interferon Alfa-2a","Drug: Ribavirin"]},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group D)","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated-interferon Alfa-2a","Drug: Ribavirin"]},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group E)","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated-interferon Alfa-2a","Drug: Ribavirin"]},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group F)","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated-interferon Alfa-2a","Drug: Ribavirin"]},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group NR)","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated-interferon Alfa-2a","Drug: Ribavirin"]}],"interventions":[{"name":"Pegylated-interferon Alfa-2a","otherNames":["Pegasys"]},{"name":"Ribavirin","otherNames":["Copegus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* evidence of CHC;\n* evidence of hepatitis C non-genotype 2 or 3;\n* compensated liver disease.\n\nExclusion Criteria:\n\n* infection with HCV genotype 2 or 3;\n* history of having received systemic antiviral therapy with activity against CHC \\<=3 months prior to start of study;\n* hepatitis A, hepatitis B or human immunodeficiency virus (HIV) infection;\n* history or evidence of a medical condition associated with chronic liver disease other than CHC.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virological Response (SVR) (Groups A and B)","description":"SVR was defined as success if the participant had HCV RNA levels \\<15 IU/mL as measured by COBAS AmpliPrep/COBAS TaqMan® HCV test at the 24-week untreated follow-up visit (HCV-RNA levels obtained at least 18 weeks after last dose of either pegylated-Interferon alfa-2a or ribavirin were considered if the 24-week untreated follow-up visit data were missing). Percentage of participants with SVR for Groups A and B was reported in this analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null},{"groupId":"OG001","value":"39.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR (Groups C, D, E, and F)","description":"SVR was defined as success if the participant had HCV RNA levels \\<15 IU/mL as measured by COBAS AmpliPrep/COBAS TaqMan® HCV test at the 24-week untreated follow-up visit (HCV-RNA levels obtained at least 18 weeks after last dose of either pegylated-Interferon alfa-2a or ribavirin were considered if the 24-week untreated follow-up visit data were missing). Percentage of participants with SVR for Groups C, D, E, and F was reported in this analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"74.2","spread":null},{"groupId":"OG002","value":"84.0","spread":null},{"groupId":"OG003","value":"84.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virological Responses (Groups A, B, C, D, E, and F)","description":"End of treatment response (ETR) was defined as \"Success\" if the HCV-RNA levels were \\<15 IU/mL at the end of treatment. Early virological response (EVR) was defined as \\>=2 log10 decrease in serum HCV RNA or undetectable serum HCV RNA (\\<15 IU/mL) at Week 12. Complete EVR was defined as \"Success\", if the HCV-RNA levels were \\<15 IU/mL at Week 12. Partial EVR was defined as \"Success\", if there was a \\>=2 log10 drop in HCV-RNA at Week 12 compared to baseline but with a level that was still \\>=15 IU/mL at that time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":null},{"groupId":"OG001","value":"76.7","spread":null},{"groupId":"OG002","value":"96.7","spread":null},{"groupId":"OG003","value":"90.3","spread":null},{"groupId":"OG004","value":"92.0","spread":null},{"groupId":"OG005","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"93.3","spread":null},{"groupId":"OG003","value":"96.8","spread":null},{"groupId":"OG004","value":"88.0","spread":null},{"groupId":"OG005","value":"92.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3.2","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":41},"commonTop":["Flu-like symptoms (fever, chills, headache, aches/pains)","Skin (injection site reactions, rashes, pruritus)","Emotional/mental (depression, anxiety, irritability, forgetfulness, confusion, anger)","Fatigue","Insomnia"]}}}